Trial Profile
Antiviral Effect of 4 Regimens of PEGASYS Plus Copegus in Patients With Genotype 1 Chronic Hepatitis C Non-Responder to Previous Peginterferon Alfa-2a Plus Ribavirin Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms SYREN
- Sponsors Roche
- 26 May 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 26 Apr 2009 Interim results presented at EASL 2009.
- 17 Sep 2008 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.